Determining the optimal management of rare cancers is challenging. This presentation will focus on special aspects of the design, conduct and analysis of clinical research studies in rare cancers. Key strategies will be illustrated with recent examples, particularly simplifying the trial question, streamlining trial processes, and striving for economies of scale by increasing the numbers of potential participants, investigators and sites.